Fish oil omega-3 fatty acids and cardio-metabolic health, alone or with statins

European Journal of Clinical Nutrition

Volumn 67, Issue 5, 2013, Pages 536-540

  Minihane, Anne Marie ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

cardiovascular; EPA and DHA; fish oils; insulin sensitivity; omega 3 fatty acids; plasma lipids

Indexed keywords

DOCOSAHEXAENOIC ACID; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INSULIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

AQUACULTURE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FISH OILS; FISHES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TRIGLYCERIDES;

ANIMALIA;

EID: 84877103043     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2013.19     Document Type: Review

References (60)

1. Nichols M, Townsend N, Scarborough P, Rayner M. European Heart Network and European Society of Cardiology: European Cardiovascular Disease Statistics 2012
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004; 364: 937-952
3. Calder PC. Mechanisms of action of (n-3) fatty acids. J Nutr 2012; 142: 592S-599SS.
4. Roth EM, Harris WS. Fish oil for primary and secondary prevention of coronary heart disease. Curr Atheroscler Rep 2010; 12: 66-72
5. Aranceta J, Perez-Rodrigo C. Recommended dietary reference intakes, nutritional goals and dietary guidelines for fat and fatty acids: A systematic review. Br J Nutr 2012; 107(Suppl 2): S8-22
6. Pan A, Chen M, Chowdhury R, Wu JH, Sun Q, Campos H et al. alpha-Linolenic acid and risk of cardiovascular disease: A systematic review and meta-Analysis. Am J Clin Nutr 2012; 96: 1262-1273
7. Burdge GC. Metabolism of alpha-linolenic acid in humans. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 161-168
8. Burdge GC, Finnegan YE, Minihane AM, Williams CM, Wootton SA. Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [13C]alpha-linolenic acid to longer-chain fatty acids and partitioning towards beta-oxidation in older men. Br J Nutr 2003; 90: 311-321
9. Welch AA, Shakya-Shrestha S, Lentjes MA, Wareham NJ, Khaw KT. Dietary intake and status of n-3 polyunsaturated fatty acids in a population of fish-eating and non-fish-eating meat-eaters, vegetarians, and vegans and the product-precursor ratio [corrected] of alpha-linolenic acid to long-chain n-3 polyunsaturated fatty acids: Results from the EPIC-Norfolk cohort. Am J Clin Nutr 2010; 92: 1040-1051
10. Scientific Advisory Committee on Nutrition (SACN) and Committee on Toxicology (COT). Advice on Fish Consumption: Benefits and Risks. TSO. The Stationary Office: Norwich, UK, 2004
11. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747-2757
12. NICE. Post Myocardial Infarction Secondary Prevention in primary and Secondary Care for Patients Following a Myocardial Infarction. Royal College of General Practioners, 2007
13. Meyer BJ, Mann NJ, Lewis JL, Milligan GC, Sinclair AJ, Howe PR. Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids 2003; 38: 391-398
14. Kennedy ET, Luo H, Ausman LM. Cost implications of alternative sources of (n-3) fatty acid consumption in the United States. J Nutr 2012; 142: 605S-609SS.
15. Vigerust NF, Bjorndal B, Bohov P, Brattelid T, Svardal A, Berge RK. Krill oil versus fish oil in modulation of inflammation and lipid metabolism in mice transgenic for TNF-Alpha. Eur J Nutr 2012, e-pub ahead of print 28 August 2012
16. Adarme-Vega TC, Lim DK, Timmins M, Vernen F, Li Y, Schenk PM. Microalgal biofactories: A promising approach towards sustainable omega-3 fatty acid production. Microb Cell Fact 2012; 11: 96
17. Whelan J, Rust C. Innovative dietary sources of n-3 fatty acids. Ann Rev Nutr 2006; 26: 75-103
18. Sayanova O, Napier JA. Transgenic oilseed crops as an alternative to fish oils. Prostaglandins Leukot Essent Fatty Acids 2011; 85: 253-260
19. Dyerberg J, Bang HO. A hypothesis on the development of acute myocardial infarction in Greenlanders. Scand J Clin Lab Inves Suppl 1982; 161: 7-13
20. Kwak SM, Myung SK, Lee YJ, Seo HG. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: A meta-Analysis of randomized, double-blind, placebocontrolled trials. Arch Int Med 2012; 172: 686-694
21. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-Analysis. JAMA 2012; 308: 1024-1033
22. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: A systematic review. Br J Nutr 2012; 107(Suppl 2): S201-S213
23. GISSI. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447-455
24. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. Atherosclerosis 2008; 197: 12-24
25. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary-And secondary-prevention studies: A systematic review. Am J Clin Nutr 2006; 84: 5-17
26. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090-1098
27. Musa-Veloso K, Binns MA, Kocenas A, Chung C, Rice H, Oppedal-Olsen H et al. Impact of low v. moderate intakes of long-chain n-3 fatty acids on risk of coronary heart disease. Br J Nutr 2011; 106: 1129-1141
28. Adkins Y, Kelley DS. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem 2010; 21: 781-792
29. Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003; 107: 2646-2652
30. Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL, Katan MB. Effect of fish oil on heart rate in humans: A meta-Analysis of randomized controlled trials. Circulation 2005; 112: 1945-1952
31. Pase MP, Grima NA, Sarris J. Do long-chain n-3 fatty acids reduce arterial stiffness̈A meta-Analysis of randomised controlled trials. Br J Nutr 2011; 106: 974-980
32. Campbell F, Dickinson HO, Critchley JA, Ford GA, Bradburn M. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. Eur J Prev Cardiol 2012; 20: 107-120
33. Calder PC. Fatty acids and inflammation: The cutting edge between food and pharma. Eur J Pharmacol 2011; 668(Suppl 1): S50-S58
34. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: A randomised controlled trial. Lancet 2003; 361: 477-485
35. Harris WS. n-3 fatty acids and serum lipoproteins: Human studies. Am J Clin Nutr 1997; 65(5 Suppl): 1645S-1654SS.
36. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: A systematic review. Atherosclerosis 2006; 189: 19-30
37. Minihane AM, Khan S, Leigh-Firbank EC, Talmud P, Wright JW, Murphy MC et al. ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2000; 20: 1990-1997
38. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: Evaluating the risks and the benefits. JAMA 2006; 296: 1885-1899
39. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279: 23-28
40. Andersen G, Harnack K, Erbersdobler HF, Somoza V. Dietary eicosapentaenoic acid and docosahexaenoic acid are more effective than alpha-linolenic acid in improving insulin sensitivity in rats. Ann Nutr Metab 2008; 52: 250-256
41. Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: A review. J Am Diet Assoc 2005; 105: 428-440
42. Tierney AC, McMonagle J, Shaw DI, Gulseth HL, Helal O, Saris WH et al. Effects of dietary fat modification on insulin sensitivity and on other risk factors of the metabolic syndrome-LIPGENE: A European randomized dietary intervention study. Int J Obes (Lond) 2011; 35: 800-809
43. Hartweg J, Perera R, Montori V, Dinneen S, Neil HA, Farmer A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; CD003205
44. Wu JH, Micha R, Imamura F, Pan A, Biggs ML, Ajaz O et al. Omega-3 fatty acids and incident type 2 diabetes: A systematic review and meta-Analysis. Br J Nutr 2012; 107(Suppl 2): S214-S227
45. Wallin A, Di Giuseppe D, Orsini N, Patel PS, Forouhi NG, Wolk A. Fish consumption, dietary long-chain n-3 fatty acids, and risk of type 2 diabetes: Systematic review and meta-Analysis of prospective studies. Diabetes Care 2012; 35: 918-929
46. Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000; 2: 200-207
47. Jackson KG, Poppitt SD, Minihane AM. Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants. Atherosclerosis 2012; 220: 22-33
48. Caslake MJ, Miles EA, Kofler BM, Lietz G, Curtis P, Armah CK et al. Effect of sex and genotype on cardiovascular biomarker response to fish oils: The FINGEN Study. Am J Clin Nutr 2008; 88: 618-629
49. Buckley R, Shewring B, Turner R, Yaqoob P, Minihane AM. Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects. Br J Nutr 2004; 92: 477-483
50. Cottin SC, Sanders TA, Hall WL. The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 2011; 70: 215-231
51. Mozaffarian D, Wu JH. (n-3) fatty acids and cardiovascular health: Are effects of EPA and DHA shared or complementarÿJ Nutr 2012; 142: 614S-625S.
52. Gotto Jr. AM, Moon JE. Management of cardiovascular risk: The importance of meeting lipid targets. Am J Cardiol 2012; 110(1 Suppl): 3A-14A.
53. Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: Strategies based on the best-Available evidence. J Clin Lipidol 2012; 6: 413-426
54. NICE. TA94: Statins for the Prevention of Cardiovascular Events. National Institute for Health and Clinical Excellence: London, 2006
55. Dujovne CA, Williams CD, Ito MK. What combination therapy with a statin, if any, would you recommend̈Curr Atheroscler Rep 2011; 13: 12-22
56. Gotto Jr. AM, Moon JE. Recent clinical studies of the effects of lipid-modifying therapies. Am J Cardiol 2012; 110(1 Suppl): 15A-26A.
57. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-Analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008; 200: 135-140
58. Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-Treated patients with persistent high triglycerides (from the ANCHOR Study). Am J Cardiol 2012; 110: 984-992
59. Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M. Effects of prescription omega-3-Acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-Associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol 2011; 5: 483-492
60. Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005; 294: 1773-1781